|Articles|November 27, 2018

OmniComm’s TrialMaster® EDC Selected for Multi-Study Cancer Research

An international biopharmaceutical company has signed a multiyear agreement with OmniComm Systems, Inc. in which the company will use OmniComm’s TrialMaster EDC technology to develop clinical studies at multiple research sites to test a cancer treatment.

Read the full release here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Content

The Unquantified Value of RBQM: Reduced Rework, Data Integrity, and Inspection Readiness

ByAbigail Dirks, MS,Sylviane de Viron,Andy Studna, Senior Editor

September 4th 2026

ACT Brief: Time Savings as RBQM Value Driver, FDA Tightens Foreign Trial Oversight, and Trusted Research Environments Versus Flat Files

ByAndy Studna, Senior Editor

September 4th 2026

© mod - © mod - stock.adobe.com

FDA Reaffirms GCP Standards Amid Growing Concerns Over Foreign Clinical Trial Data

ByAndy Studna, Senior Editor

September 3rd 2026

Why Time Savings Is the Largest Driver of RBQM's Financial Value

ByAbigail Dirks, MS,Sylviane de Viron,Andy Studna, Senior Editor

September 3rd 2026

ACT Brief: Human Readiness as Operational Foundation, Early Phase Capacity Consolidation, and AI-Driven Patient Matching Scale

ByAndy Studna, Senior Editor

September 3rd 2026

Trending on Applied Clinical Trials Online

Fortrea to Acquire Worldwide Clinical Trials' Early Phase Services Division in $45 Million Deal

Agentic AI and the Administrative Backbone of Clinical Trials: Why the Operating Model Has to Change First

FDA Reaffirms GCP Standards Amid Growing Concerns Over Foreign Clinical Trial Data

Why Time Savings Is the Largest Driver of RBQM's Financial Value

Introducing The Human Side of Clinical Trials